Egalet announced its partner OraPharma, a division of Valeant Pharmaceuticals, has begun promoting SPRIX (ketorolac tromethamine) Nasal Spray to more than 9,000 dentists and oral surgeons across the United States.
"With the launch of OraPharma's team of 141 sales professionals supporting marketing of SPRIX Nasal Spray to its target dentists and oral surgeons, we are substantially expanding our commercial reach in a specialty area outside our current commercial footprint," said Patrick Shea, chief commercial officer at Egalet. "With our own salesforce, our partner Ascend Therapeutics and OraPharma, we now have more than 200 sales representatives educating on the benefits and risks of SPRIX Nasal Spray."
Under the agreement announced earlier this month, the OraPharma sales team will promote SPRIX Nasal Spray along with their own portfolio of products to their target dentists and oral surgeons. SPRIX Nasal Spray is a nonsteroidal anti-inflammatory drug (NSAID) indicated in adults for short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level.